The 18 panel dip card (SM-DOA-6185FUO) from 12 Panel Now is the most comprehensive emerging-substance dip card in the range below 19 panels. It covers 17 drug substance panels — the complete 12 panel professional baseline plus five specialty additions — alongside built-in ADLTX specimen validity checks (pH, Specific Gravity, Creatinine) in a single Forensic Use Only card. Currently on short date sale at $1.03 per card through 12/14/2026, making it the most cost-effective comprehensive emerging-substance dip card currently available from 12 Panel Now.

The five specialty panels added over the 12 panel dip card baseline are: EtG (alcohol metabolite), FEN (fentanyl), KET (ketamine), KRA (kratom), and TRA (tramadol). Every one of these five substances passes every panel of every standard 12 panel configuration completely undetected.

The five specialty panels and what they detect that no standard panel can:

EtG / Ethyl Glucuronide at 300 ng/mL — 80-Hour Alcohol Monitoring

EtG is the primary urinary metabolite of alcohol, detectable for 24 to 80 hours post-consumption. For programs running weekly urine collections, EtG at 300 ng/mL covers approximately 70% of the standard 168-hour inter-test interval — providing alcohol abstinence documentation where no breathalyzer or direct alcohol test can reach. Per SAMHSA MAT guidelines, concurrent alcohol monitoring is a documented compliance requirement. No standard multi-panel drug test includes an EtG panel. This is the same EtG panel used in the 14 panel dip card range at the same 300 ng/mL cutoff.

FEN / Fentanyl at 20 ng/mL — Federal Mandate Compliance

Fentanyl is approximately 50 to 100 times more potent than morphine per NIDA fentanyl research, meaning illicit use occurs at urinary concentrations far below what would trigger a standard OPI antibody. FEN at 20 ng/mL provides dedicated point-of-care fentanyl detection for 12 to 48 hours after exposure. Added to SAMHSA federal workplace testing panels effective July 2025. For programs that need clinical-grade FEN detection at 1 ng/mL under CLIA Waived certification, see the 17 panel CLIA dip card.

KET / Ketamine at 1000 ng/mL — Dissociative Anesthetic Detection

Ketamine is a DEA Schedule III dissociative anesthetic used clinically for anesthesia and increasingly prescribed for treatment-resistant depression. It is misused recreationally as Special K. It does not cross-react with PCP, BZO, or any other standard panel antibody — a specimen containing any ketamine concentration returns a negative on every standard multi-panel test. The dedicated KET panel at 1000 ng/mL on the 18 panel card provides point-of-care detection for 1 to 4 days post-use using a ketamine-specific antibody. Programs needing standalone Ketamine detection can also use the 16 panel KRA/KET card.

KRA / Kratom at 500 ng/mL — Legal Opioid Receptor Substance

Kratom (Mitragyna speciosa) binds to mu-opioid receptors but its active alkaloids (mitragynine, 7-hydroxymitragynine) are structurally distinct from all opioid compounds detected by standard OPI, BUP, or MTD antibodies. Legally sold at retail in most US states, Kratom is documented in MAT, treatment, and correctional populations as a self-managed opioid substitute or opioid-adjacent substance. The dedicated KRA panel at 500 ng/mL is the only available point-of-care rapid urine detection method for kratom. Also available as a dedicated specialty panel in the 16 panel dip card and 17 panel dip card ranges.

TRA / Tramadol at 1000 ng/mL — The Prescription Opioid Every Standard OPI Panel Misses

Tramadol (Ultram) is a Schedule IV prescription opioid analgesic with dual mechanism — weak mu-opioid receptor agonism and serotonin-norepinephrine reuptake inhibition — and a molecular structure that does not cross-react with any OPI, OXY, BUP, or MTD antibody. A person taking therapeutic or misuse-level tramadol at any dose returns a completely negative result on every opioid panel of any standard multi-panel drug test. The dedicated TRA panel at 1000 ng/mL closes this specific detection gap. Per NIDA prescription drug misuse data, tramadol misuse is documented in forensic and treatment populations where it is used as a detectable-free opioid substitute.

ADLTX — pH, Specific Gravity, Creatinine — Simultaneous Specimen Validity

The three ADLTX specimen validity markers run simultaneously alongside all 17 drug panels in the same 5-minute dip event. pH outside the 4.5 to 8.5 normal urinary range flags chemical adulteration. Specific Gravity below 1.003 flags dilution. Creatinine below 2 mg/dL flags substitution or extreme dilution. For forensic programs where results may enter legal proceedings, ADLTX documentation provides simultaneous specimen integrity evidence from the same collection event with no additional test strip, no additional cost, and no additional workflow step. The same ADLTX format appears on the 19 panel dip card.

18 Panel vs 19 Panel: The One Substance Difference

The 18 panel card and the 19 panel card are identical in every panel except one: the 19 panel card adds Gabapentin (GABA) at 1000 ng/mL as the 19th panel position. Both cards include the same 17 drug panels and the same ADLTX validity checks. Programs where Gabapentin monitoring is not a priority should order the 18 panel card at $1.03 (short date). Programs where Gabapentin monitoring is a priority — or where the price difference matters — should order the 19 panel card at $1.05 standard price, which actually delivers more coverage at a comparable per-card cost.